The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis

This item appears in the following Collection(s)

Available in accordance with the Publisher Policy. Please refer to the publisher's site for terms of use.

Search Repository


My Account

Statistics